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Abstract
Background: The purpose of this study was to evaluate the performance a newly developed
nanocrystalline hydroxyapatite, OSTIM® following functional implantation in femoral sites in thirty-
eight sheep for 1, 2 or 3 months. Ostim® 35 was compared to an established calcium phosphate,
Alpha BSM®.
Methods: Biomechanical testing, μ-CT analysis, histological and histomorphological analyses were
conducted to compare the treatments including evaluation of bone regeneration level, material
degradation, implant biomechanical characteristics.
Results: The micro-computed tomography (μCT) analysis and macroscopic observations showed
that Ostim® seemed to diffuse easily particularly when the defects were created in a cancellous
bone area. Alpha BSM® remained in the defect.
The performance of Ostim was good in terms of mechanical properties that were similar to Alpha
BSM® and the histological analysis showed that the bone regeneration was better with Ostim® than
with Alpha BSM®. The histomorphometric analysis confirmed the qualitative analysis and showed
more bone ingrowth inside the implanted material with Ostim® when compared to Alpha BSM ®
at all time points.
Conclusions: The successful bone healing with osseous consolidation verifies the importance of
the nanocrystalline hydroxyapatite in the treatment of metaphyseal osseous volume defects in the
metaphyseal spongiosa.
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Background
Operative reconstruction of bone defects beyond a certain
size still remains a challenge to trauma and orthopedic
surgeons. Every year, millions of people worldwide are
suffering from bone defects arising from trauma, tumor or
bone diseases. In approximately 10% of all traumatically
related loss of bone structure or even tumor related bone
defects, spontaneous bone healing is not able to restore
the required physiological stability. In such cases bone
replacement materials are often necessary to reconstruct
the anatomical morphology and restore stability of the
bone[1].
The use of autologous pelvic bone is still considered as the
gold standard in the reconstruction of bone defects
because of its unsurpassed biological activity even in
implant sites with low osteogenic potential. Pelvic bone
harvesting from the iliac crest does, however, presents
unacceptable rates of morbidity at the grafting site and at
the same time may only provide a limited amount of can-
cellous bone[2-8]. Chronic pain can be present in up to
39% of patients at the donor site after iliac crest harvest-
ing[2]. Other published complications include: fractures,
infection, nerve and arterial injury[7].
Other bone sources include bone allografts which carry
the potential of disease transmission, immunogenicity
and possibly lower union rates[4,9]. Furthermore, the
structural, mechanical, and resorption properties of allo-
grafts are usually much altered by processing, preserva-
tion, and sterilization techniques[4,10,11]. The relative
concerns over the use of either autograft or allograft have
led to the development of numerous bone graft substi-
tutes[12-20].
In the ideal case artificial bone replacement materials
should present a similar structure and composition to
human bone and thus be able to present bone function.
The materials should be osteoconductive and osteoinduc-
tive by allowing osteoblast and osteoclast activity. At
present there are over 100 approved bone replacement
materials in Germany alone. The spectrum encompasses
mainly hydroxyapatite ceramics, absorbable calcium
phosphate cements, various metals, plastics and a variety
of composites. The most commonly used synthetic min-
eral substitutes for bone defect and trauma applications as
implant coatings and defect fillers are hydroxyapatite
cements, which have already undergone comprehensive
animal testing and have also established themselves in
many surgical procedures on human patients[18-39].
Ostim® represents a brand new development among the
purely synthetically produced and rapidly absorbable
Hydroxyapatite compounds. It has been widely and suc-
cessfully used in the fields of oral and maxillofacial sur-
gery and orthopedic and trauma surgery[40-46].
The aim of the following study was to compare the newly
developed Ostim®  with tricalcium phosphate cement
Alpha-BSM®, an already established bone replacement
material, in relation to their biocompatibility and bone
ingrowth in a bone defect.
Methods
Material properties of the hydroxyapatite compounds 
used
Ostim®
Ostim®, (aap biomaterials GmbH, Dieburg, Germany) is a
newly developed, fully synthetic and fully resorbable
injectable nanocrystalline paste [Ca10(PO4)6(OH)2] and
consists of a suspension of pure HA in water prepared by
a wet chemical reaction. The needle shaped HA crystals
form agglomerates as shown by transmission electron
microscopy (see fig. 1). XRD Analysis reveals an average
crystallite size of 19 nm. Ostim® paste does not harden
after application into the bone and is free of endothermal
heating. It is characterized by a large bioactive specific sur-
face area of 106 m2 g-1[47]. The atomic ratio of calcium-
phosphorus is 1.67.
The product is supplied in a ready-to-use syringe to which
a needle or a flexible 5 cm nozzle can be attached in order
to inject the paste into deeper voids.
Alpha BSM®
Alpha BSM® (ETEX Corp, CAMBRIDGE, MA 02139, USA),
an established calcium phosphate cement, is an endother-
mically setting apatitic calcium phosphate bone substi-
tute. The final product (means after the conversion
reaction is complete) consists of purely crystalline HA
with an average crystallite size of 12-14 nm. Alpha BSM®
has a paste like consistency until it is injected and hardens
at body temperature. In 20 min it achieves complete con-
version and mechanical strength. The reported mechani-
cal strength is 15 MPa[34]. Specific surface area of the
dried product is 78 m²/g.
None of two materials has macropores and both are
applied as wet pastes. The water content of Ostim is 65%,
freshly prepared alpha-BSM paste has a water content of
55%.
Animal experiment protocol
Permission was granted to conduct all parts of our animal
experiments we applied for (authorization number 59036
by BIOMATECH Ethical Committee on March 16, 2007).
The sheep model has been used in intra-osseous implan-
tation studies and is recognized by International Regula-
tory organizations[48,49]. Thirty eight with three inBMC Musculoskeletal Disorders 2009, 10:164 http://www.biomedcentral.com/1471-2474/10/164
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reserve (38 + 3) female sheep (Ovisaries), between 53 and
73 kg and between 2 and 5 years old were used for the ani-
mal experiments.
The evaluation of the performance and the biocompatibil-
ity of a bone substitute was tested following functional
implantation in femoral sites in thirty-eight sheep for 1, 2
or 3 months (total of 76 sites). The Ostim® material (n =
38 sites) was compared to Alpha-BSM® (n = 38 sites) fol-
lowing implantation in a cancellous bone defect (see
additional file 1).
Each animal received an implantation of each bone
replacement material in the cancellous bone of the right
and left medial distal femoral epiphysis respectively. The
treatment allocation was randomly assigned between the
right and left leg. Pre-medication and anesthesia were per-
formed by intravenous injection of thiopental-pentobar-
bital mixture (NESDONAL®, MERIAL, France;
pentobarbital sodique, CEVA Santé animale, France) and
atropine (Atropinum sulfuricum, AGUETTANT, France)
followed by inhalation of a O2 - isoflurane (1-4%) mix-
ture. Each animal received an analgesic (flunixine, FINA-
DYNE®  Injectable, Schering-Plough, France) pre-
operatively. As a prophylactic measure, perioperative anti-
biotics penicillin-procaine and penicillin benzathine
(DUPHAPEN® LA, FORT DODGE, France) was given.
Using standard aseptic techniques, a cutaneous incision
was made on the medial face of the knee. The medial con-
dyle of the stifle joint of each animal was exposed by blunt
dissection of the subcutaneous tissue and the fascia. The
muscle and joint capsule were gently dissected and the
supracondyle bone area was approached. The periosteum
was carefully removed from the femoral epiphysis and
metaphysis to expose the implant site. A core drill was
used to drill a 10 mm diameter × 15 mm deep hole in the
distal femoral epiphysis. After drilling the defect to the
required depth, an extractor was inserted and driven down
to the bottom of the defect. The extractor was turned to
break the bone trabecula at the bottom of the defect.
Depth of the defect was measured. Each defect was filled
with either the test or the control article. The incision was
then closed by closing the subcutaneous layers one by one
with absorbable sutures (Vicryl 2-0 and Vicryl 1,
ETHICON, France), and the skin layer was closed using
surgical staples. The animal was repositioned and the
other bone replacement material implanted in the same
fashion. At the appropriate termination interval, the des-
ignated sheep were terminated by lethal injection of bar-
biturate (DOLETHALND, VETOQUINOL, France). A
macroscopic examination of the implanted femoral epi-
physes was performed. The epiphyses were then harvested
and identified. The epiphyses from the 2 and 3 months
animals were placed in 10% buffered formalin. After fixa-
tion, these samples were submitted for μ-CT analysis. The
epiphyses from the 3 months interval were arbitrarily
divided so that sixteen sites sampled from eight animals
(eight test and eight control) were selected for biome-
chanical testing and the remaining sites were fixed in 10%
buffered formalin.
Preparation of the samples
The epiphysis from the eight designated sheep from the 3
months termination interval was subjected to biomechan-
ical testing. The soft tissues were removed from these sam-
ples. The defect was located using X-rays. A diamond saw
was used to obtain two parallel and flat surfaces. The
approximate final dimensions of the sample were 4 × 4 ×
1.8 cm (see fig 2). Care was taken not to disrupt the
implant from the defect site at this stage.
The test specimens were prepared so that the implantation
site were in the centre of the sample. The tissue samples
Sample dimensions Figure 1
Sample dimensions. The test specimens were prepared so 
that the implantation site was in the centre of the sample. 
The tissue samples were provided in physiological serum and 
the trials were performed within 48 h after removal.BMC Musculoskeletal Disorders 2009, 10:164 http://www.biomedcentral.com/1471-2474/10/164
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were provided in physiological serum and the trials were
performed within 48 h after removal. Their thickness has
been measured using a slide caliper at the implantation
point.
Biomechanical testing
First, the thickness of the samples was measured with a
calliper. Following thickness measurements, the samples
were immersed in room temperature saline solution. The
samples were submitted to an indentation test. Load was
applied axially to the specimens by a pin with a diameter
of 4 mm and with a displacement speed of 0.4 mm/min
until failure. To determine the mechanical characteristics
of the samples, the data collected were stiffness and
Young's modulus, yield point, maximum load and corre-
sponding stress and strain. This biomechanical testing was
also performed on four non implanted test articles.
Non implanted samples were prepared by placing Ostim
samples in a cylindrical container of a diameter of 12 mm
and a height of 20 mm. They were tested immediately
thereafter.
-CT analysis
Following fixation, the epiphyses sites for the 2 months
animals and the ten animals designated from the 3
months interval were used to quantify the mean BV/TV
(Bone + substitute volume/Total bone defect volume).
The μCT measurements were conducted at ETH Zürich by
means of a μCT 80, Scanco Medical AG, Switzerland. The
measured data was filtered using a constrained Gaissian
filter with finite filter support (1 Voxel) and filter width (σ
= 1.2). The images were then binarized to separate the
object from the background using a global thresholding
procedure. For density analysis a cylinder of 11.7 mm in
diameter and 17 mm length was analyzed. The cylinder
dimension was obtained from the μCT images and was
chosen to represent the original defect as good as possible.
For this the cylinder was morphed along the axis of the
defect zone in the following way: A circle with 11.7 mm
was positioned over the defect zone on the first and the
last μCT slice of the given range of the substitute (17 mm)
and the cylinder was morphed in-between. Within this
cylinder the apparent density was computed as the ratio of
substitute versus background.
Histopathological technique
Each implant site and surrounding tissue was isolated
using a band saw. After labelling and fixing in 10% buff-
ered formalin solution, the sites were longitudinally
divided in two blocks. One half of each site was dehy-
drated in alcohol solutions of increasing concentrations,
cleared in xylene, decalcified and embedded in paraffin.
Embedded sites were then longitudinally cut at 5 to 7 μm
using a microtome (MICROM®, France). One paraffin sec-
tion per site was prepared and stained with Masson's tri-
chrome. The other half of each site was dehydrated in
alcohol solutions at increasing concentrations, cleared in
xylene and embedded in polymethylmethacrylate
(PMMA). One longitudinal section was prepared using
the Exakt system [25,50]. The resin sections were stained
with a modified Paragon.
Qualitative evaluation of implanted sites
Histological sections were observed using a Nikon micro-
scope (Eclipse E600) fitted with ×4, ×10, ×25 and ×40
objectives. Semi-quantitative analysis was performed in
accordance with ISO 10993-6 standard: local tolerance
criteria and performance were analyzed and graded.
(necrosis, fibrinous exudate, tissue degeneration, inflam-
matory cells, fibrous tissue, osteolysis, newly formed
bone, osteointegration, osteoconduction, and material
degradation.)
Particular attention was devoted to:
- the neoformed bone, the direct bone/implant interface
and the osteoconduction process
- inflammatory reaction,
- presence of fibrosis
- material degradation.
The semi-quantitative scoring system is shown in addi-
tional file 2
Quantitative histomorphometry of implanted sites
The histological slides obtained from resin blocks were
evaluated under a Zeiss Axioscope microscope fitted with
×5, ×10, ×20 and ×40 objectives and equipped with a
color image analyzing system SAMBA® (SAMBA TECH-
Ostim® agglomerates in transmission electron microscopy Figure 2
Ostim® agglomerates in transmission electron 
microscopy.
4 cm 
15 mm
4 cm 
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NOLOGIES, France). Two standard areas of investigation
were located peripherally to the Bone/Implant junction,
and two standard areas of investigation were located inter-
nally to the Bone/Implant junction.
In these areas of investigation, whenever possible, the fol-
lowing parameters were measured in the control resin
slides and in the test resin slides at one, two and three
months:
- bone to implant contact, BIC (expressed in percentage)
- bone density around the material (expressed in percent-
age)
- bone density inside the material (expressed in percent-
age)
At each time point a statistical analysis (ANOVA method)
was performed for these 3 parameters, considering control
versus test article.
Statistical analysis
The statistical tests used for a comparison between groups
for the main parameters of biomechanical testing and
quantitative histological analysis were Mann and Whitney
or ANOVA tests performed with a software (SPSS® version
14.0, edited by SPSS Inc, Chicago).
Results
Biomechanical testing
Biomechanical testing was performed on 16 samples from
the 3 month time-period (see additional file 3). At yield
point, the stress was higher in the Alpha-BSM® Group and
the strain was higher in the Ostim® group. Resistance,
stress and strain were higher in the Alpha-BSM® group.
Elasticity, stiffness and Young modulus were higher in the
Ostim® group. However, no statistically significant differ-
ences were observed for any parameters. The biomechan-
ical testing performed on four non implanted test articles
showed a maximum load for resistance and yield point at
least ten times lower than the values observed after
implantation, suggesting a significant hardening and/or
bone ingrowth during the 3 month implantation period.
CT analysis
All samples were successfully scanned with μCT. From
these measurements it can be seen that the Alpha BSM
material was very dense and had a very well confined
shape. For this reason, the median for these groups was
higher than 95%, which means that there was almost no
porosity. The mean BV/TV (Bone + substitute volume/
Total volume) values were found to be 95.2% for the 2
month Alpha BSM sites and 90.4% for the 3 month Alpha
BSM sites. The Ostim material was in most samples very
granular and showed some tendency to penetrate into the
surrounding area. However, bone ingrowth into the sub-
stitute could not be determined as it was not possible to
automatically differentiate the bone from the substitute
due to similar contrast. In samples where the substitute
disappeared from the original defect, there was only little
bone formation that could be seen in the defect. The
apparent density in the Ostim sites was lower than in
Alpha BSM sites. The mean BV/TV values were found to be
68.3% for the 2 month Ostim sites and 79.9% for the 3
month Ostim sites. The relatively large range indicates
that these samples were much more inhomogeneous as
the control samples. The μCT measurement were limited
by the fact that the bone replacement materials had a very
similar attenuation for X-rays as bone and that thus two
phases could not be separated automatically. It was
observed that the Ostim article seemed to diffuse easily in
particular when the defects were created in a spongious
bone area, close to the diaphysis or the joint-space nar-
rowing whereas the more compact Alpha BSM article used
in similar conditions stayed in the defect. This led to a
lower apparent density within the defects treated with the
Ostim when compared to the Alpha BSM (see fig. 3a - b).
Microscopic analysis of femoral sites at 1 month (see
additional file 4)
Alpha BSM
All ten implanted sites were identified on the histological
sections. These sites were filled with a dense green-red
stained biomaterial (on paraffin sections) with diffuse
optically empty round cavities. On resin sections the
material was very dense, dark pink colored and it showed
no signs of open porosity. Limited signs of inflammatory
reaction were visible in the area surrounding the product
and were accompanied by the presence of macrophages
and giant multinucleated cells. The Alpha-BSM showed
Defects centralized, confined (a) Alpha-BSM® and (b) Ostim® Figure 3
Defects centralized, confined (a) Alpha-BSM® and (b) 
Ostim®. The μCT images after three months of the bone 
replacement material implantation.
  
a                 b BMC Musculoskeletal Disorders 2009, 10:164 http://www.biomedcentral.com/1471-2474/10/164
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good signs of osseointegration. A slight grade of fibrocon-
nective tissue was often observed at the bone-implant
interface. Almost no signs of implant degradation were
visible. Few osteoblasts were observed directly on the sur-
face of the implant. The overall osteoconduction process
and newly formed bone were of limited grade and local-
ized onto the interface between the edge of the original
bone defect and the implant surface. No or very limited
signs of bone ingrowth within the implant were observed,
likely due to the absence of open porosity of the implant.
As a consequence the bone density within the implant was
of very limited grade (see fig. 4)
Ostim®
Ten implant sites were identified. The implant was recog-
nized as green stained particles (on paraffin sections) of
various sizes ranging from a few μm to 100-200 μm. In
resin sections, the implant particles often formed central
dense and peripheral loose aggregates, thus delimiting
widely open interconnected peripheral porosities. No
continuity with the neighboring articular cartilage could
be observed microscopically on both paraffin and resin
sections. A slight to moderate grade of inflammatory reac-
tion was observed in the area surrounding the implant
particles and was accompanied by the presence of a vascu-
larized fibroconnective inflammatory tissue, macro-
phages and multinucleated giant cells. The Ostim® 35
bone substitute showed good signs of osseointegration
(moderate grade), osteoconduction (moderate grade) and
bone density within the implant (slight to moderate
grade). Notable was a degree of heterogeneity was
observed amongst the animals regarding new bone forma-
tion and bone density. Limited signs of material degrada-
tion were observed (see fig. 5).
Microscopic analysis of femoral sites at 2 months (see
additional file 4)
Alpha BSM
The ten sites implanted with Alpha BSM showed a similar
appearance compared to those observed at 1 month, with
only slight signs of peripheral degradation after 2 months.
Almost no residual signs of inflammatory reaction were
visible: no biologically significant amounts of macro-
phages, giant multinucleated cells and fibroconnective tis-
sue were observed. The osseointegration of the Alpha-
BSM® slightly progressed with few signs of penetration of
thin bone trabecules within the outer portion of the bone
substitute. Few signs of bone remodeling were observed
(see fig. 6)
Ostim®
The overall aspects of Ostim® after 2 months were compa-
rable to those observed at 1 month, with some sites show-
ing a heterogeneous structure of the material. The
degradation process of the test article progressed signifi-
cantly between 1 and 2 months with an overall reduced
size of the particles in many animals. No continuity with
the neighboring articular cartilage could be observed
microscopically on both paraffin and resin sections.
Alpha-BSM® at 1 month Figure 4
Alpha-BSM® at 1 month. Masson's tricrome staining and 
2× magnification of decalcified bone with calcium phosphate 
appearing as a still relatively compact matter. The osteocon-
duction process and newly formed bone were of limited 
grade and localized onto the interface (black arrows) 
between the edge of the original bone defect and the implant 
surface. (New bone = blue, Alpha-BSM = red)
Ostim® at 1 month Figure 5
Ostim® at 1 month. Masson's tricrome staining and 2× 
magnification of decalcified bone 1 month after Ostim 
implantation. Particles of the HA-nanocrystalline paste are 
seen as round structures of different size in the bone mar-
row and within the bone trabecular tissue. The interface 
between implant material and host bone is indicated by the 
black arrows.BMC Musculoskeletal Disorders 2009, 10:164 http://www.biomedcentral.com/1471-2474/10/164
Page 7 of 11
(page number not for citation purposes)
Ostim® particles were associated with few signs of inflam-
matory reaction consisting of a limited grade of macro-
phages and giant multinucleated cells. A variable grade of
fibrocytic tissue was visible within the implanted bone
defect. Mean osteoconduction and bone density parame-
ters progressed very significantly. Few signs of bone
remodeling were observed (see fig. 7).
Microscopic analysis of femoral sites at 3 months (see
additional file 4)
Alpha-BSM®
Ten implanted sites were identified on the histological
sections. In paraffin sections the sites were filled with a
dense red stained biomaterial with diffuse optically empty
round cavities. In resin sections, the material was still
quite dense, but some signs of open porosity were
observed. Limited signs of inflammatory reaction were
visible in the area surrounding the product and were
accompanied by the presence of macrophages. Moderate
evidences of bone ingrowth within the implant were
observed. As a consequence the bone density within and
around the implant was of slight to moderate grade, and
a steady and homogeneous progression of new bone for-
mation was observed amongst the animals in resin sec-
tions. Some signs of bone remodeling were observed in
one animal only on resin sections (see fig. 8)
Ostim®
The overall histopathological picture was very similar to
the one observed at 2 months. The mean amount of
inflammatory reaction surrounding the implant particles
was slight and tended to decrease over time. Still there
were great individual variations regarding the amount of
fibrous tissue ranging from absent to marked grade,
resulting in respectively high or low bone density. Ostim®
showed good signs of mean osseointegration, osteocon-
duction and bone density within the implant that
improved over time. Moderate signs of material degrada-
tion were constantly observed, which increased over time.
Some signs of bone remodeling were observed in resin
sections (see fig. 9).
Quantitative histolomorphometrical analysis
At early time points, Ostim® showed much better micro-
scopic signs of osteointegration, osteoconduction and
overall bone ingrowth when compared to the Alpha-
BSM®. After 2 and 3 months, the bone regeneration level
within the Ostim® treated sites was better than the Alpha-
BSM® treated sites, but new bone formation tended to
Alpha-BSM at 2 months Figure 6
Alpha-BSM at 2 months. Masson's tricrome staining and 
20× magnification of decalcified bone 2 months after Alpha-
BSM® implantation.
Ostim® at 2 months Figure 7
Ostim® at 2 months. Modified paragon staining and 20× 
magnification of Ostim® core surrounded by new bone for-
mation.
Alpha-BSM® at 3 months Figure 8
Alpha-BSM® at 3 months. Modified paragon staining and 
10× magnification of Alpha BSM® cement on the left upper 
quadrant of the image surrounded by newly formed bone.BMC Musculoskeletal Disorders 2009, 10:164 http://www.biomedcentral.com/1471-2474/10/164
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slow down when compared to the steadier progression
and fewer inter-individual variations observed with
Alpha-BSM® (see additional file 5 and 6).
Bone to Implant Contact (BIC)
After 1 month, bone to implant contact was significantly
different between alpha BSM and Ostim groups (p =
0.004). Bone to implant contact around the material was
found higher in the alpha BSM than in the Ostim group.
This difference was transient and not observed at later
time-points (see additional file 7).
Bone density inside the material
After 1 and 2 months, bone density inside the material
was significantly different between Alpha-BSM®  and
Ostim® groups. Bone density was higher in Ostim® group
when compared to Alpha-BSM® as no bone was found
inside the Alpha-BSM® material. After 3 months, this same
parameter was again significantly higher in the Ostim®
group as compared to the Alpha-BSM® group (p = 0.012)
although some bone was found inside the Alpha-BSM®
material (see fig. 10).
Bone density around the material did not show statisti-
cally significant variations at all considered time-points.
Discussion and Conclusions
There were a number of attempts in the past to replace
bone loss with bone replacement materials. Hamilton in
1881 used disinfected sponges and Gluck in 1891
implanted ivory into bone defects. Dreesmann even tried
gypsum in 1892. In the 20th century Maatz experimented
with bovine bone and Tarsoly filled the defects with egg
shells[51]. Modern bone replacement materials com-
posed of calcium phosphate are either extracted from
bovine cancellous bone or are produced syntheti-
cally[14,18,52,53]. The requirements of an ideal bone
replacement material have not changed over the past 30
years: simple application, osteoconductive properties,
and complete resobarbility during bone ingrowth[53,54].
Alpha-BSM® fulfils these requirements very well as a syn-
thetic calcium phosphate bone replacement material.
Compared to other calcium phosphates which require five
years or more to be resorbed by the host bone[55,56],
Alpha BSM®  appears to undergo more rapid resorp-
tion[22,52]. It does, however, have less compressive
strength than other types of cements [34]. Compared to
autologous cancellous bone, calcium phosphate cements
have shown superior compressive strength. Welch et al
reported a significantly lower secondary loss of correction
with the use of Alpha-BSM®, in the treatment of tibia head
fractures in goats compared to autologous spongiosa[34].
Russell also revealed a significantly lower subsidence in
tibia head fractures with the use of Alpha-BSM® compared
to autologous bone grafts in the scope of a multicentre
study with 119 Patients[39].
The cement microstructure of Alpha-BSM®, which results
from a reaction of precipitation, is not equivalent to the
crystalline structure of human bone[18,57,58]. The
nanocrystalline structure of Ostim® on the other hand
resembles human bone much closer (Calcium/Posphate
ratio of 1,675 and specific surface area of 106 m2g-1 is syn-
thesized by a wet chemical reaction of precipitation under
Ostim® at 3 months Figure 9
Ostim® at 3 months. Modified paragon staining and 5× 
magnification of non-decalcified bone 3 months after Ostim® 
implantation. Ostim® bone showed good osseointegration 
and bone remodeling.
Bone density inside the material in percent Figure 10
Bone density inside the material in percent. Bone 
ingrowth was detected only 3 months postoperatively with 
alpha BSM a bone substitute.BMC Musculoskeletal Disorders 2009, 10:164 http://www.biomedcentral.com/1471-2474/10/164
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permanent pH control using CaO dispersed in water
under constant stirring to maintain a suspension state and
H3PO4 as starting material [47,58]. Ostim®  has been
observed as needle shaped HA crystals forming agglomer-
ates in transmission electron microscopy [1,47]. Accord-
ing to the hypotheses put forward by Constanz and
Knaack such HA-compounds accelerate the bony
ingrowth into the CSD as they closely mimic the required
resorptive and osseointegrative properties of poor crystal-
line apatitic structure of natural bone[52,57,58]. Moreo-
ver Kilian et al also presented evidence of angiogenesis
within bone defects filled with nanocrystalline hydroxya-
patite [59,1,60]. These properties appear to explain the
significantly increased ingrowth of bone of the Ostim®
group compared to the Alpha-BSM® group. There was no
significant difference between the two materials with
regard to their biomechanical stability.
Ostim® 35 showed limited signs of degradation after 1
month but degradation increased over time and was of
moderate grade after 3 months in our experimental series.
This confirms the results obtained in a number of differ-
ent experimental animal models of other studies. Grigor-
yan et al described the rapid bone ingrowth at a low
complication rate following the treatment of jaw defects
with Ostim® in dogs in 2000 [61]. Our own animal exper-
iments dealing with the filling of critical size defects with
Ostim in New Zealand white rabbits also resulted in swift
and uniform bone ingrowth[62]. The results were further
enhanced by the additional use of a sintered hydroxyapa-
tite ceramic[62]. Ostim® was always present in the bone
after 60 days following implantation, as in the present
study[62]. Laschke reported a guided neovascularization
directed toward areas of Ostim® degradation in Syrian
golden hamsters [63]. Spiess further confirmed the good
biocompatibility, osteoconductivity and bone ingrowth
in New Zealand whites, but reported a halt in the Ostim®
degradation process 6 weeks following implantation[64].
Comprehensive clinical experience of using the hydrated
HA-paste as a void filling exists in the field of maxillofa-
cial surgery. Various stomatology publications describe an
accelerated fracture healing and bone density increase at a
high degree of tolerance. In 1996 Zuev treated 395
patients with jaw defects and peridontal abscesses. The
complication rate of the 200 patients in the Ostim group
was at 1.5% compared to 3.6% in the group with 195
patients treated with allografts[44]. Bezrukow achieved
excellent results in 1998 after treating 49 patients with
Ostim® following cystectomy of benign cyst-tumours of
the jaw. The defects in all 49 patients were replaced with
fresh bone three months following the defect filling [43].
Gerlachfilled 44 mandibular cysts with Ostim®  and
reported complete material resorption with an extemely
low complication rate[65]. Strietzel et al performed a lat-
eral alveolar ridge augmentation with Ostim®  in 14
patients. Six months later histological results showed
good bone ingrowth of the defect and small amounts of
Ostim® remnants [46].
Ostim® in combination with conventional or angularly
stable osteosynthesis has also been successfully used in
the field of traumatology. Particularly good results were
achieved in prospective cohort studies with patients for
the treatment of radial fractures, with closed intraarticular
calcaneus fractures, as well as tibia compression fractures
[40-42]. Histological examinations of bone harvested
from patients during elective metal removal, have shown
excellent bone ingrowth into the past bone defect with
well structured cortical and cancellous bone tissue and
without any inflammatory reaction orosteofibrosis. The
implanted material was mainly resorbed[62].
Our data verifies the importance of the nanocrystalline
hydroxyapatite in the treatment of metaphyseal osseous
volume defects in the metaphyseal spongiosa, even
though this study was done on an experimental animal
model. Further clinical studies need to be conducted to
validate the significance of Ostim in human bone defects.
Due to its good biocompatibility and high rates of resorp-
tion we can see a number of indications for the use of
Ostim in the field of traumatology. In our opinion the
application of Ostim® should always be combined with
some form of stable osteosynthesis, preferably with an
angularly stable plate, due to its lack of dimensional sta-
bility.
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